The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

17 Jul 2023 15:00

Arix Bioscience PLC (ARIX) Holding(s) in Company 17-Jul-2023 / 15:00 GMT/BST


TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BD045071

Issuer Name

ARIX BIOSCIENCE PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Ruffer LLP

City of registered office (if applicable)

London

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

14-Jul-2023

6. Date on which Issuer notified

17-Jul-2023

7. Total positions of person(s) subject to the notification obligation

.

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

4.977220

0.000000

4.977220

6440000

Position of previous notification (if applicable)

 

 

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BD045071

6440000

0

4.977220

0.000000

Sub Total 8.A

6440000

4.977220%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

 

 

 

 

Sub Total 8.B1

 

 

 

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

 

 

 

 

 

Sub Total 8.B2

 

 

 

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

 

 

 

 

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

Ruffer LLP now controls the voting rights over 6,440,000 shares (less than 5% of the voting rights) of Arix Bioscience plc which are held by the discretionary clients of Ruffer LLP and its subsidiaries (the voting of which is all controlled by Ruffer LLP).This change from 5% to less than 5% is due to the sale of 80,000 shares by Ruffer LLP on 14 July 2023.

12. Date of Completion

17-Jul-2023

13. Place Of Completion

Ruffer LLP


Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
ISIN:GB00BD045071
Category Code:HOL
TIDM:ARIX
LEI Code:213800OVT3AHQCXNIX43
OAM Categories: 2.3. Major shareholding notifications
Sequence No.:258222
EQS News ID:1681769
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
22nd Jun 20224:45 pmEQSHolding(s) in Company
22nd Jun 20227:00 amEQSNotice of Investor Presentation
22nd Jun 20227:00 amEQSNotice of Investor Presentation
9th Jun 20227:00 amEQSUnaudited NAV for May 2022
9th Jun 20227:00 amEQSUnaudited NAV for May 2022
7th Jun 20224:45 pmEQSResult of Annual General Meeting 2022
12th May 20229:00 amRNSCommunications with Shareholders
12th May 20227:00 amRNSPublication of Annual Report & Notice of AGM
11th May 20227:01 amEQSUnaudited NAV for April
9th May 20223:29 pmEQSClinical Development Update from Portfolio Company LogicBio
5th May 20227:01 amEQSFinancial Results for the Year Ended 31 December 2021
4th May 20226:39 pmRNSStatement Regarding Arix Bioscience plc
4th May 20227:01 amEQSTR-1: Notification of major holdings
29th Apr 202210:45 amEQSUnaudited NAV and Notice of Financial Results
5th Apr 20224:29 pmEQSImara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia
14th Mar 202211:32 amEQSCorporate update from portfolio company Harpoon Therapeutics
25th Feb 20225:30 pmRNSClosed Period Notification
24th Feb 20228:00 amRNSCompany Secretary Change
8th Feb 20227:20 amEQSTotal Voting Rights
2nd Feb 20221:06 pmEQSArix Bioscience PLC: Clinical development update from portfolio company LogicBio
22nd Dec 202111:05 amEQSArix Bioscience PLC: Arix Bioscience co-leads $31 million Series A financing for new portfolio company Sorriso Pharmaceuticals
17th Dec 202111:13 amEQSArix Bioscience PLC: Director/PDMR Shareholdings
17th Dec 20217:00 amRNSDirector/PDMR Shareholding
15th Dec 20218:14 amEQSArix Bioscience PLC: Depixus raises €30.6M (£26.1 million) in Series A Financing
13th Dec 20213:54 pmEQSArix Bioscience PLC: Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021
13th Dec 20213:51 pmEQSArix Bioscience PLC: Autolus Therapeutics presents positive obe-cel data at the American Society of Hematology (ASH) Annual Meeting 2021
17th Nov 20215:04 pmEQSImara Announces Interim Analysis Data From Forte Phase 2b Clinical Trial Of Tovinontrine (Imr-687) In Transfusion-Dependent Subjects With Beta-Thalassemia
8th Nov 20215:34 pmEQSTransaction in own shares
8th Nov 20211:00 pmEQSArix Bioscience PLC: Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform
8th Nov 20217:01 amEQSArix Managing Director to Participate in Fireside Chat at the Jefferies Healthcare Conference
1st Nov 20217:01 amEQSTotal Voting Rights
29th Oct 20217:00 amEQSAura Biosciences prices Nasdaq IPO
18th Oct 20214:48 pmEQSLogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children
18th Oct 20217:00 amEQSBusiness Update and Cancellation of Share Buyback
15th Oct 20215:30 pmEQSTransaction in own shares
14th Oct 20215:30 pmEQSTransaction in own shares
13th Oct 20215:30 pmEQSTransaction in own shares
13th Oct 20215:28 pmEQSTR1: Notification of Major Shareholding
12th Oct 20215:30 pmEQSTransaction in own shares
12th Oct 20211:02 pmEQSAura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting
11th Oct 20215:30 pmEQSTransaction in own shares
8th Oct 20215:30 pmEQSTransaction in own shares
8th Oct 202110:11 amEQSPyxis Oncology prices Nasdaq IPO - Update
8th Oct 20217:00 amEQSPyxis Oncology prices Nasdaq IPO
7th Oct 20215:30 pmEQSTransaction in own shares
6th Oct 20215:30 pmEQSTransaction in own shares
6th Oct 20217:00 amEQSBoard Changes
5th Oct 20215:30 pmEQSTransaction in own shares
4th Oct 20215:30 pmEQSTransaction in own shares
1st Oct 20215:30 pmEQSTransaction in own shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.